The Medicon Valley Inhalation Consortium (MVIC) has announced that the 2021 Medicon Valley Inhalation Symposium (MVIS), which was to take place on October 13-14 in Lund, Sweden, has been postponed indefinitely. The MVIC training session scheduled for October 11-12 in Lund will go ahead. MVIC called the postponement, "Very unfortunate, frustrating and even … [Read more...] about Medicon Valley Inhalation Symposium postponed
News
Vivera gets US patents for Zicoh smart inhaler
Within one week in August, Vivera Pharmaceuticals has announced the issuance of two US patents covering its Zicoh smart inhaler technology. The first is US Patent No. 11,083,850 ("Secure smart dosing system with automated delivery, measurement, and management") and the second is US Patent No. 11,090,449 ("Smart inhaler device with automated dose delivery, measurement, … [Read more...] about Vivera gets US patents for Zicoh smart inhaler
Aerami’s inhaled imatinib for PAH gets orphan drug designation
The FDA has granted orphan drug designation to Aerami Therapeutics's AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said. Aerami initiated a Phase 1 trial of AER– 901 in June 2021, with results expected by the end of the year. In June 2020, Aerami announced a partnership with inhalation CDMO Vectura for … [Read more...] about Aerami’s inhaled imatinib for PAH gets orphan drug designation
Lupin launches Luforbec beclometasone/formoterol MDI in the UK
Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June 2021. According to Lupin, the Luforbec inhaler will be manufactured at the company's facilities in the US and India. The company cited UK prescribing data … [Read more...] about Lupin launches Luforbec beclometasone/formoterol MDI in the UK
Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx's SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the … [Read more...] about Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
FDA pre-approval inspection of Liquidia manufacturing facility has been completed
According to Liquidia Corporation, the FDA has completed a pre-approval inspection of Liquidia's facility in Morrisville, North Carolina, USA, where the company will manufacture LIQ861 dry powder treprostinil if approved. No Form 483 observations were issued. The company added that it has received notice that the agency will also require a pre-approval inspection of a … [Read more...] about FDA pre-approval inspection of Liquidia manufacturing facility has been completed
Positive Phase 1 results for Receptor Life Sciences’ RLS103 CBD DPI
Receptor Life Sciences (RLS) has published data from a Phase 1 PK trial of its RLS103 dry powder cannabidiol (CBD) in the Journal of Pharmaceutical Sciences demonstrating significantly greater bioavailability for the inhaled CBD than for Epidiolex oral CBD solution. RLS announced completion of its pre-IND meeting with the FDA in January 2021. Receptor licensed … [Read more...] about Positive Phase 1 results for Receptor Life Sciences’ RLS103 CBD DPI
Cellics partners with HCmed on delivery of inhaled nanosponges
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the … [Read more...] about Cellics partners with HCmed on delivery of inhaled nanosponges
Virpax says it intends to submit NDA for its MMS019 nasal spray as an OTC anti-viral barrier
Virpax Pharmaceuticals said that it is encouraged by the FDA response to its IND for MMS019 "high-density molecular masking spray" which the company is developing as an anti-viral barrier. According to Virpax, the company now intends to begin clinical development with the goal of submitting an NDA for MMS019 to the FDA's Office of Non-Prescription Drugs. The company … [Read more...] about Virpax says it intends to submit NDA for its MMS019 nasal spray as an OTC anti-viral barrier
Positive results from pilot study of Tiziana’s intranasal Foralumab in mild to moderate COVID-19
Tiziana Life Sciences has published results from a pilot study of its intranasal Foralumab in mild to moderate COVID-19 demonstrating that nasal administration of the human anti-CD3 monoclonal antibody was well tolerated and significantly reduced lung inflammation in non-hospitalized patients. In 2019, the company announced positive Phase 1 results for the intranasal … [Read more...] about Positive results from pilot study of Tiziana’s intranasal Foralumab in mild to moderate COVID-19